Abstract: Erythropoietin (EPO), a renal cytokine, regulates proliferation, differentiation and maturation of erythroid cells. Recombinant human erythropoietin (rH-EPO) is well known to correct anemia in patients with chronic renal failure undergoing dialysis. Recent studies have reported several non-hematopoietical effects of EPO. Erythropoietin receptors have been discovered in a variety of tissues, including the cardiovascular system. Recently published data including recent patent documented an enhancement of cardiac function in patients with heart failure receiving EPO treatment. Furthermore, experiments carried out in animal models of ischemia/reperfusion (IR) injury have shown a significant reduction in infarct size following EPO treatment. Other beneficial effects of EPO are related to its pro-angiogenic action on endothelial cells, which might be of potential value in patients with ischemic heart disease. Taken together, these findings suggest that EPO may be clinically useful as an adjunct in the treatment of different cardiovascular conditions, besides the simple correction of anemia. This review will focus on the pleiotropic effects of EPO in the cardiovascular system and its promising novel applications.
INTRODUCTION
Erythropoietin (EPO) is a renal cytokine that regulates proliferation and differentiation of erythroid cells. It is synthesized by peritubular cells in the cortex-medullary border of the kidney and in the liver during fetal and neonatal development. Ischemia stimulates mammalian cells to express a variety of proteins, including hypoxia inducible factor 1a (HIF-1a). Expression of HIF-1a increases exponentially, as cellular O 2 concentration decreases [1] . Increasing levels of HIF-1a, in turn, lead to upregulation of various proteins, including EPO, which plays a crucial role in erythropoiesis, by promoting survival and proliferation of erythroid precursor cells [2] . EPO production is also directly stimulated by hypoxia, increasing dramatically when hemoglobin (Hb) drops below 12g/dL. As a consequence, the reticulocyte count in peripheral blood augments in 3 to 4 days and clinically significant amelioration in hematocrit (HCT) occurs in about 2 weeks.
Since the cloning of the EPO gene in 1983, initiation of recombinant human erythropoietin (rH-EPO) therapy in 1985 and approval for its clinical use in 1989, rH-EPO has been widely used in the treatment of anemia associated with various chronic conditions. These include, but are not limited to, end stage renal disease and malignancy. The long acting analog of rH-EPO, darbepoietin, has a longer half-life (25.3 hours) than the 8.5 hours of regular rH-EPO. It can be administered once a week, or even every two weeks, to attain the same level of Hb that is achieved when giving rH-EPO three times a week [3] . Increase in Hb and HCT, due to administration of exogenous EPO, results in improved oxygen carrying capacity of blood. Erythropoietin receptor antibodies have been reported for treating anemia [4] .
In patients with anemia secondary toa end stage renal disease (ESRD), rH-EPO has been shown to reverse the unfavorable hemodynamic changes, which develop secondary to the high output state. Commonly reported changes are decreased indices of left ventricular size, volume, and mass with improvement of ejection fraction. In addition, there is an improvement in cardiac output and cardiac index [5] . EPO increases patients' sense of well-being, reduces fatigue, increases appetite and work capacity, and improves libido [6] . Side effects are mostly limited to mild hypertension and rarely thrombosis. EPO, EPO mimetics, blood substitutes, such as modified hemoglobin solutions and perfluorochemicals, blood transfusion, and endogenous stimulation of red blood cell production by altitude or hypoxic rooms have been used by athletes to increase oxygen transport in an attempt to improve endurance capacity [7] .
Anemia is common in patients with chronic congestive heart failure (CHF) and, although plasma EPO levels are increased in patients with CHF, they are still insufficient to counterbalance the decreased Hb levels [8] . A recent study in anemic CHF patients showed that rh-EPO therapy not only corrected Hb levels, as expected, but significantly improved cardiac function and quality of life [9] . The exact mechanism of these effects is unknown. In a review by Noakes, it was pointed out that if the role of EPO was limited to increasing the oxygen carrying capacity of blood, EPO should be helpful only in "all-out exercise, lasting a few minutes", where performance is dependent on oxygen delivery to the muscles. Since, in reality, EPO proved to exert long-lasting effects, enduring for several weeks after a short course, other mechanisms of action should be implicated [10] .
Recently published data suggests that administration of rH-EPO plays a protective role in vascular diseases [11] [12] [13] . Ischemia/reperfusion (IR) experiments in rat heart and brain showed a dramatic reduction in the extent of infarct size, by means of EPO pre-treatment. Although the favorable effects of these EPO-related changes are still mostly unknown, possible mechanisms of cardioprotection seem to relate to the anti-apoptotic and -oxidative properties of EPO [14, 15] . Conversely, the beneficial effect of EPO in conditions targeting the vascular system may be related to its proangiogenic potential [16] . In this review, we discuss the pleiotropic effects of EPO in the cardiovascular system, as well as its potential novel applications in the clinical setting.
MECHANISM OF ACTION

EPO Receptor
EPO receptor (EPOr) is a transmembrane (type 1) receptor with a WSXWS motif in the extracellular domain. It belongs to the cytokine receptor superfamily and consists of eight exons (extracellular domains: 1-5; membrane spanning domain: 6; intracellular domains: 7, 8) [17] . The intracellular domain does not have any kinase activity. Upon interaction between EPO and its cognate receptor, EPOr undergoes homodimerization, with subsequent activation of janus kinase 2 [18] . Synthetic Peptide dimer is reported by Palani for its usage as agonists of the erythropoietin (EPOr) [19] , finally resulting in tyrosine phosphorylation of EPOr, signal transduction and activation of transcription factor 5 (STAT-5) [20] , as well as a variety of other targets. A number of proteins with Src homology 2 (SH2) domains, such as PI3 kinase, become associated and consequently activated. PI3 kinase, for instance, suppresses apoptosis via activation of its downstream effector Akt [21] . The EPO-EPOr interaction also leads to activation of ras/MAPK pathways [22] , and to initiation of nuclear factor-kB (NF-kB) dependent transcription [23, 24] .
Rise in intracellular calcium is another major effect of EPO-EPOr interaction. EPO binding to EPOr results in phosphorylation and subsequent translocation of PLC-γ from the cytosol to the plasma membrane [25] . At this level, PLCgamma interacts with other subunits in a multimeric complex, leading to generation and release of IP3, which, in turn, induces calcium release from the intracellular stores [25] . Calcium channel proteins may also become phosphorylated during the EPOr mediated activation [26] .
In addition to erythroid precursors, EPOr is also expressed on megakaryocytes, vascular smooth muscle cells, endothelial cells, skeletal myoblasts, neurons, nephrons, breast carcinoma, neuronal retinal cells as well as cardiac myocytes [27 -37] .
Anti-Apoptotic Effects of EPO
The physiologic effects of EPO go far beyond erythropoiesis. It is now well established that EPO exerts its action not only on erytroid cells, but also on a number of other tissues and organs carrying EPO receptors, such as muscle (smooth, skeletal and myocardium), brain, spinal cord, retina, gonads, lung, gut, pancreas, uterus, and kidney [38] . The treatment of ischemia induced organ dysfunction i.e ischemia induced renal failure, myocardial ischemia, intestinal ischemia and cerebral ischemia is patented [39] . In the embryo, EPO is required for cardiac myocyte proliferation [40] . Effects described in this section may not involve the cardiovascular system directly, but serve as a basis for the hypothesis that antiapoptotic action of EPO is applicable to the heart. Most of the anti-apoptotic effects of EPO are known from the hematological field. EPO is the primary regulator of erythropoiesis, and promotes the proliferation and differentiation of erythroid progenitor cells [2] . It does so, at least in part, by preventing immature erythroblasts from undergoing apoptotic cell death. As previously described, EPO binds to its cognate receptor inducing simultaneous activation of various signaling pathways, including the MAPK p42/44, JAK2-STAT5 and the PI-3-AKT proteins. Studies performed on human early erythroid cell lines suggested that EPOmodulated cell proliferation is mainly due to activation of MAPK p42/44 or JAK2-STAT5 signaling pathway, while inhibition of apoptosis is chiefly achieved by activation of the PI3K-AKT axis or the JAK2-STAT5 signaling pathway [41] . In the latter case, phosphorylated JAK2 triggers the activation of STAT5, with subsequent translocation of the transcription factor into the nucleus, where it binds to specific DNA response elements, inducing a cascade of cellular responses, which include upregulation of antiapoptotic genes, such as bcl-2 and bcl-XL [42, 43] .
The anti-apoptotic mechanism described above is not only important in erythropoiesis, but also appears to play an important role in other conditions characterized by apoptoticmediated cell loss, such as stroke, retinal diseases, and cardiac conditions, such as myocardial infarction and congestive heart failure [44] [45] [46] [47] . Abundant EPO receptors are present in white matter and motor neurons of the spinal cord. EPO, given to rodents immediately after experimental spinal cord injury, provided a nearly complete recovery of motor function. The difference between EPO-treated and saline-treated animals, which was already noticeable after 1 hour, became dramatic after 48 hours. At the histopathological evaluation, untreated animals showed a widespread neuronal degeneration, which was remarkably reduced in the spinal cord of animals receiving EPO treatment [48, 49] .
Several reports have indicated that in the brain, like in the kidney, endogenous production of EPO is stimulated by hypoxia, and supplementation with exogenous EPO can protect neurons from ischemia. Pretreatment with EPO twenty four hours prior to cerebral ischemia attenuated the damage from subsequent brain infarction, reducing infarct size, minimizing the occurrence of apoptotic cell death and limiting the extent of irreversible changes in the area surrounding the infarction. More specifically with respect to the antiapoptotic activity of EPO, a recent report by Chong et al. documented that in cerebral microvasculature endothelial cells (EC) exposed to radical-induced injury, EPO treatment reduced the extent of activation of the mitochondria initiated pathway by modulating the induction of apoptotic protease-activating factor-1 (Apaf-1) as well as the release of cytochrome c. Consistent with the modulation of Apaf-1 and the release of cytochrome c, EPO also inhibits the activation of caspase-9 and caspase-3-like activities [50] . Same group of investigators in another study concluded that EPO can offer novel cytoprotection during ischemic vascular injury through direct modulation of Akt1 phosphorylation, mitochondrial membrane potential, and cysteine protease activity [51] . Furthermore, in rats with embolic stroke, EPO increased the density of microvessels at the stroke boundary and improved functional recovery [52] . In line with these findings, in rats exposed to a 60 minute reversible cerebral ischemia, EPO infusion (5000 U/kg) at the moment of occlusion reduced infarct size by 75% and markedly attenuated the occurrence of neuronal apoptosis [53] . The beneficial effects of EPO treatment have also been documented in the peripheral nervous system, where EPO was reported to ameliorate the decrease in nerve conduction velocity occurring in a rat animal model of diabetic neuropathy [54] . Likewise, in a model of ischemic retinal injury, EPO given at the time of or immediately after the ischemic insult dramatically decreased ischemia-induced retinal neuron injury, while soluble EPO-receptors, by antagonizing intrinsic EPO, exacerbated the extent of the ischemic damage [55] . Finally, in rats undergoing nearly complete nephrectomy, subcutaneous darbepoietin, injected once a week, improved survival, as compared to salinetreated controls (63% versus 33%; P<0.05), despite equal HCT in both groups. Some of the documented beneficial effects, which, once again, seem to be mainly related to an antiapoptotic mechanism, included attenuation of endothelial and tubulointerstitial injury, as well as amelioration in vascular and glomerulosclerosis [56] .
Role of EPO in Angiogenesis
In addition to its anti-apoptotic effects, other important physiological properties of EPO have been recently described. For instance, a study of Juul and collaborators revealed the presence of EPO and EPOr in human fetal tissue. Although the heart showed minor amounts of EPO, the EPOr was abundantly expressed in the myocardium, as gestation progressed, indicating its persistence in the adult cardiac tissue [57] . The expression of EPOr in the fully developed heart has been confirmed by a more recent study carried out in the rat heart, detecting the presence of EPOr in endothelial cells, fibroblasts and, to a lesser extent, cardiomyocytes [58] . Experiments with mice deleted (knocked-out) for the gene expressing EPO and EPOr provided more evidence for its role in cardiac tissue, as both EPO -/-and EPOr -/-mice suffer from ventricular hypoplasia [57] . This defect appears to be independent from the hypoxic state and is likely due to a reduction in the number of proliferating cardiac myocytes in the ventricular myocardium. To support this concept, additional experiments were performed under cultured conditions. In these experiments, Wu and coworkers found that EPO acts as a mitogen in isolated cardiomyocytes from EPO -/-and wild type mice, while it has no effect in EPOr -/-mice [59] . These findings, taken together, strongly suggest that EPO and its receptor, at least during fetal life, stimulate cardiomyocyte proliferation.
An interesting observation in the experiments with EPO knockout mice was that the vascular network in the mutant rodent was also severely affected, with a disorganized structure. Instead of inter-connected, fine vascular networks, the EPOr -/-heart showed dilated and independent vascular clumps [59] . Indirect evidence suggests that subtotally nephrectomized rats with moderate renal failure, and presumably low levels of EPO, showed a lack of microvessels in the heart [60] . The expression of EPO-r has been demonstrated on endothelial cells in vivo and in vitro [61] . Stimulation of cultured endothelial cells with rH-EPO resulted in cell proliferation and differentiation into vascular structures and incubation of rat aortic rings with rH-EPO was related to endothelial sprouting [62, 63] . Importantly, Jaquet and colleagues, comparing the angiogenic properties of EPO and vascular endothelial growth factor (VEGF) on cardiac endothelial cells, documented that both proteins have an equal angiogenic potential, which suggests a role for rH-EPO in vasoproliferative processes [64] .
Subsequent effects of increasing levels of HIF-1α are not only upregulation of EPO, as previously stated, but also of VEGF, whose ability to cause angiogenesis was documented in the myocardium [65] . Recent data have shown that VEGF might play a role in heart failure, particularly in idiopathic dilated cardiomyopathy (IDC) [66] . Decreased capillarization in IDC disproportionate to the rate of hypertrophy was observed and may contribute to the demand-supply mismatch [67] . The reason for this seemingly decreased angiogenic capacity might be the reduced expression of VEGF in IDC. On the other hand, CHF is also associated with progressive cardiac cell loss, due, at least in part, to an apoptotic mechanism [45, 68] . Since both factors, namely decreased capillarization and increased apoptosis, seem to play a relevant role in the pathogenesis of heart failure, it ensues that the use of rH-EPO, by virtue of its anti-apoptotic and pro-angiogenic effects, may be clinically valuable to counteract, or even prevent, development and progression of cardiac decompensation.
More recently, endothelial progenitor cells (EPCs), derived from the bone marrow, have been isolated from adult peripheral blood and shown to play a role in physiological and pathophysiological neovascularization [69, 70] . Heeschen and collaborators provided evidence that EPC-induced neovascularization, in part, was achieved by enhancing EPO mobilization from the bone marrow. In addition, they demonstrated, in a model of hind-limb ischemia, that EPO increased capillary density by 1.6-fold, as compared to control mice. The pathophysiological relevance of these findings was further elucidated in patients with coronary heart disease, in whom, serum EPO levels, which were found to be notably higher than controls, significantly associated with an increased amount of functionally active EPCs. Hence, we may speculate that an additional justification for the clinical use of EPO as a therapeutic adjunct in patients with coronary artery disease or congestive heart failure would be the benefit ensuing from the mobilization of bone marrow-derived EPCs [9] .
rH-EPO IN MYOCARDIAL ISCHEMIA AND INFARCTION
Unlike necrotic cell death, which is collectively recognized as the prototype of ischemic cell death, apoptosis has been implicated in the pathogenesis of cardiac ischemia/reperfusion injury (IRI) only in the last decade. Caspases are enzymes, acting in an ordered cascade mechanism, responsible for the initiation, execution and finalization of the apoptotic process, and their inhibition, by means of various agents, was repeatedly proved to result in improved post-ischemic recovery of cardiac function due to an antiapoptotic mechanism of action. In line with these findings, several recent studies demonstrated beneficial effects of EPO, utterly unrelated to hematopoiesis, in the setting of experimental IRI.
Myocardial contractility, for instance, measured as +/-dP/dT in an in vivo mouse model of IRI, dramatically improved after treatment with EPO [71] . In another in vivo model of IRI, rats given a single dose of EPO (3000 U/kg) immediately after the ligation of the left coronary artery, exhibited a 50% reduction in apoptosis, and a decrease in infarct size [72] . Likewise, isolated rat hearts exposed to IRI and perfused with EPO exhibited reduced cell death, as well as ameliorated functional recovery and coronary flow, versus untreated animals [73] . Starting within the first week after surgery, through an eight week follow-up, end-systolic anddiastolic dimensions of the left ventricle were significantly lower in EPO treated rats, while fractional shortening was higher, even though the increase in HCT was not statistically significant [73] .
In a similar rat model of myocardial infarction, EPO, given either before ligation of the coronary artery or at reperfusion, and, afterwards, daily for the entire duration of the study, improved left ventricular end diastolic pressure (LVEDP) and myocardial wall stress versus saline-treated controls [74] .
Treatment with EPO after induced hemorrhagic shock, but before resuscitation, improved liver and kidney function in rats. In the same study, EPO administration after coronary ligation caused a significant reduction in infarct size, while incubation with EPO of cultured rat cardiac myoblasts reduced the extent of DNA fragmentation induced by either serum deprivation or hydrogen peroxide-mediated oxidative stress [75] .
Consistent results have also been obtained in a few remarkable studies using an in vivo rabbit model of cardiac ischemia. Parsa and colleagues, for instance, administered a single dose of EPO (5000 U/kg) to rabbits exposed to IRI, at the time of coronary artery occlusion [76] . On day three, although no difference in HCT was documented, EPO administration induced a significant amelioration in cardiac contractility and relaxation, evaluated as dP/dTmax and dP/dTmin, as well as a reduction in infarct size, associated with an attenuation of apoptotic cell death. In another study carried out by the same investigators, two different dosing regimens of EPO have been tested in an identical experimental model of IRI. EPO was given either at a dose of 1000 U/kg or 5000 U/kg at the time of ischemia, at the time of reperfusion, or 12 hours prior to ischemia. Although a reduction in infarct size was documented in all the EPOtreated groups, the uppermost functional amelioration, evaluated as postischemic recovery in LVEDP, was observed when EPO was given at higher concentration 12 hours before ischemia [77] . In a subsequent study carried out in the ischemic/reperfused rat heart, Lipsic and coworkers showed that the antiapoptotic effect of EPO was even more marked when it was administered after the onset of reperfusion hours, instead of 2 hours before IRI, or at the start of ischemia [78] .
In support of the findings showing that EPO-mediated cardioprotection is independent from its effects on hemopoiesis, Fiordaliso and colleagues reported that carbamylated EPO, a derivative of EPO lacking hematopoietic activity, dramatically decreased necrotic and apoptotic myocyte cell death in the rat heart exposed to IRI [79] .
Although researchers have mainly focused on the antiapoptotic effects exerted by EPO on cardiac myocytes, this does not rule out the possibility of concurrent alternative EPO-mediated mechanisms of protection. Ischemia alone is only able to initiate the apoptotic cascade, while reperfusion is required to complete the apoptotic program [80] . Moreover, in the early stages of reperfusion, apoptosis is first seen in endothelial cells and then spreads to surrounding cardiomyocytes, suggesting reperfusion induced release of pro-apoptotic mediators from endothelial cells [81] . Since EPOr is also expressed on cardiac endothelial cells, it is tempting to speculate that rH-EPO be also capable of reducing the extent endothelial cell apoptosis, reducing therefore the extent of ensuing secondary myocyte cell death and associated endothelial dysfunction [82] .
ROLE OF rH-EPO IN CHF
Anemia in heart failure has a complex pathogenesis including decreased production of EPO by the kidneys, hemodilution, intestinal malabsorption with subsequent iron deficiency, and chronic aspirin use, oftentimes associated with concomitant warfarin intake. In addition, some proinflammatory cytokines, such as tumor necrosis factor, may cause EPO resistance and generate the so called "anemia of chronic illness" [83, 84] .
EPO levels, which are increased in HF, poorly correlate with Hb levels and the clinical use of plasma EPO concentration as an independent prognostic factor seems to be very promising [85] .
The triad of chronic renal insufficiency, anemia and heart failure was named recently the "cardio-renal anemia syndrome". Components of this "syndrome" can precipitate one another, forming a vicious cycle. In pathophysiologic terms, anemia causes tissue hypoxia, which, in turn, leads to peripheral vasodilatation, with subsequent reduction in vascular resistance and blood pressure. This triggers an opposing sympathetic stimulation, with ensuing increase in heart rate and stroke volume, as well as renal vasoconstriction, which decreases renal blood flow and glomerular filtration rate, activating the renin-angiotensin-aldosterone system (RAAS) and the release of antidiuretic hormone. Subsequently, the plasma volume expands; the ventricles dilate and undergo remodeling with subsequent myocyte cell death due to a combined necrotic and apoptotic mechanism. As HF develops, the progressive deterioration of cardiac function further activates RAAS, as well as release of several factors, including tumor necrosis factor-α, all of which concur to aggravate even more cardiac performance and therefore renal perfusion, with ensuing completion of the vicious cycle [86] .
Prevalence of anemia in patients with HF varies depending on the subset of patients and on the definition of anemia. Indeed, anemia worsens progressively with the severity of HF. According to Silverberg and collaborators, anemia, defined as Hb <12 g/dL, was present in 55.6% of all patients with HF [87] . It increased from 9.1% and mean Hb 13.7 g % in NYHA class I to 79.1% and mean Hb 10.9 g% in NYHA class IV. Anemia was associated with higher mortality even after an adjustment for other comorbidities [88] . A retrospective analysis of the RENAISSANCE trial showed that anemia was associated with higher mortality and hospitalization rates in patients with HF [89] . High prevalence and a detrimental role of anemia in HF have been extensively covered in several reviews by Felker, Katz, Caiola and McBride [90] [91] [92] [93] , just to cite a few of them published in the last few years.
Analysis of the SOLVD database (6563 patients) documented that reduced kidney function and lower HTC in patients with left ventricular systolic dysfunction were risk factors for all-cause mortality (p < 0.001). After adjustment for other factors, a 10 ml/min/m 2 lower glomerular filtration rate and a 1% lower HCT were associated with a 1.064 and 1.027 higher risk for mortality, respectively. With both lower glomerular filtration rate and lower HCT, the risk was higher (p=0.022 for the interaction) than predicted by both factors independently [94] . In line with these findings, in the OPTIME trial, it was shown that every unit of fall in Hb level increased the risk of death or readmission for HF by 13% [90] .
The most compelling data on EPO therapy in HF belong to the group of Silverberg and collaborators. Patients with HF resistant to maximally tolerated doses of standard medications were treated with IV iron and subcutaneous (SQ) EPO [95] [96] [97] [98] . The correction of anemia, defined as Hb<12 g/dL, and maintenance of normal iron stores caused a 91.9% reduction of hospital admissions, an increase in ejection fraction, improvement in NYHA class, and stabilization in glomerular filtration rate, which was declining steadily by 1 ml/min/month before the treatment. In the same randomized study, after a mean eight months follow-up, the EPO group demonstrated no HF related deaths versus four out of sixteen in the no treatment group. The NYHA class improved by 42.1% versus a worsening by 11.4%; while ejection fraction increased by 5.5% versus a decrease by 5.4% in EPO treated group, as compared to controls. Furthermore, serum creatinine, which did not change in patients receiving EPO, increased by 28.6% in the control group. Finally, need for oral and IV furosemide decreased by 51.3% and 91.3% respectively in the EPO group, versus an increase by 28.5% and 28.0% in control patients.
In the only double-blind, randomized, placebo-controlled trial by Mancini and coworkers, EPO increased peak oxygen consumption, exercise duration, and six minute walking test performance in HF patients [99] . They used EPO 5000 U SQ three times a week for three months, with uptitration to 10,000 U three times a week if Hb increment was <1g/dL in 4 weeks, accompanied with ferrous gluconate and folate. No thrombotic events or hypertension were reported in the EPO treated group.
In the multicenter randomized clinical trial STAMINA HeFT, about 300 HF patients with Hb< 12.5 g/dl are being evaluated. Exercise tolerance is being assessed by treadmill stress test executed at baseline, after six months, and one year in patients treated with darbepoetin alfa (subcutaneous injections every two weeks for one year) or placebo [100] .
Although reatment with rH-EPO has shown promise in CHF patients, yet its mechanism of action remains elusive. George J et al. explored the effect of chronic treatment with rH-EPO on the number and functional properties of endothelial progenitor cells (EPC) in CHF patients. Twentyeight patients with CHF treated with rH-EPO for a mean period of 28 months were compared to a matched group (n = 28) with regard to the number of circulating hematopoietic and endothelial stem cells (either CD34+, CD34+/CD45+, CD34+/CD133+, CD34+/VEGF-R2+ or CD34+/CD133+/ VEGF-R2+) as well as their proliferative and adhesive capacity [4] . EPC from rH-EPO-treated patients exhibited enhanced proliferation as well as a trend towards adhesion to cultured endothelial cells prior to and following stimulation with TNF-alpha. Addition of EPO to EPC from healthy subjects dose-dependently increased their proliferation and adhesion to fibronectin, cultured endothelial cells, and cardiomyocytes. These effects were significantly reduced in the presence of phosphatidylinositol (PI) 3-kinase inhibitors. The study concluded that chronic rH-EPO treatment is associated with an increase in the adhesive and proliferative properties of circulating EPC in patients with CHF [101] .
In a recent study by Desai A et al., accelerated atherosclerosis in rH-EPO treated ESRD patients raises concerns and needs further validation. A reduction in nitric oxide (NO) availability may be linked to EPO-induced vascular dysfunction. Furthermore, chronic kidney disease per se is thought to result in a state of NO deficiency. The study conducted by the authors suggest that EPO may exert proatherogenic activity by augmenting the cytokine-induced expression of monocyte-chemoattractant protein-1 (MCP-1) in human umbilical vein endothelial cells (HUVECs) and by stimulating the proliferation of HUVECs and human vascular smooth muscle cells (HVSMCs). Augmentation of MCP-1 expression appears to be linked to EPO-induced downregulation of endothelial NO synthase (ecNOS). NO released from a series of synthetic donor compounds suppressed the EPO-mediated augmentation of cytokineinduced MCP-1 expression [102] .
Potential drug interaction is a concern in HF patients. The majority of patients with HF are on ACE inhibitors. As described earlier, the concentration of EPO is increased in HF and correlates with its severity. Treatment of dilated cardiomyopathy with enalapril decreases EPO level back to normal, probably due to correction of renal hypoxia [103, 104] . Some data demonstrate that ACE inhibitors can inhibit erythropoiesis via suppression of bone marrow response to EPO or angiotensin-mediated EPO production. For example, in altitude-induced polycytemia, just 5 mg of enalapril a day for two years reduced Hb concentration [105] . Withdrawal of ACE inhibitors in hypertensive chronic hemodialysis patients receiving EPO may result in an increase in HCT level [106] .
Clinical data are controversial. When 48 hemodialysis patients were divided into two groups depending on their ACE-inhibitors use, there was no difference in the dose of EPO or the concentration of HCT [107] . A different study, however, reported the need to increase the dose of EPO in renal patients on ACE inhibitors in order to achieve the same level on HCT [108] .
Despite some potential adverse effects, early studies in heart failure patients with anemia suggest that rH-EPO therapy is safe and effective in reducing left ventricular hypertrophy, enhancing exercise performance and increasing ejection fraction. New studies with longer follow-up are warranted, but already existing data are very encouraging in terms of therapeutic gains in this widely spread condition.
CURRENT & FUTURE DEVELOPMENTS
Although the direct erythropoietic action of EPO is well known and widely used in the clinical setting, EPO-mediated antiapoptotic properties have been described only recently, opening new horizons in both clinical investigation and therapeutic approach. The large reduction of infarct size and the surprising postischemic recovery in cardiac function induced by EPO treatment in experimental models of IRI are more than encouraging, suggesting a possible clinical use of EPO as an adjunct to the standard treatment of acute coronary syndromes.
Likewise, HF patients, frequently undertreated for anemia, may represent another population with the potential to benefit from EPO treatment. However, albeit most recent studies report dramatic improvement in patients with HF receiving EPO, new controlled clinical trials in large and diverse groups of patients are warranted to accurately define the extent of the benefit, narrowing clinical indications, and identifying potential long term adverse effects.
